Investors should have known better to blame Biogen for Alzheimer's drug failure, says WSJ reporter

2:20 PM ET Thu, 21 March 2019

Charley Grant, Wall Street Journal, joins 'The Exchange' to discuss the fall of Biogen's stock after the company announced it would end trials for its experimental Alzheimer's drug.